Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD

Blood (2009) 114 (22): 636.

https://doi.org/10.1182/blood.V114.22.636.636

Published: 2009

Journal Articles

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

John F Lyons, PhD, Matthew S Squires, John Goodall, Murray Yule, Farhad Ravandi, MD, James Foran, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4159.

https://doi.org/10.1182/blood.V114.22.4159.4159

Published: 2009

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD

Blood (2009) 114 (22): 584.

https://doi.org/10.1182/blood.V114.22.584.584

Published: 2009

Journal Articles

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

John Goodall, Matthew S Squires, Vicky Lock, Farhad Ravandi, MBBS, Hagop M Kantarjian, James Foran, MD, Neil T Thompson, John F Lyons

Blood (2008) 112 (11): 1613.

https://doi.org/10.1182/blood.V112.11.1613.1613

Published: 2008

Journal Articles

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

James Foran, MD, Angelina The, MD, Pam Dixon, RN, Marcel Devetten, MD, Mikkael Sekeres, MD

Blood (2007) 110 (11): 1831.

https://doi.org/10.1182/blood.V110.11.1831.1831

Published: 2007

Journal Articles

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

Mitchell R. Smith, MD, PhD, Lijun Zhang, Leo I. Gordon, MD, James Foran, MD, Brad Kahl, MD, Randy D. Gascoyne, MD, Ranjana Advani, MD, Elisabeth Paietta, MD, Edie Weller, PhD, Sandra J. Horning, MD

Blood (2007) 110 (11): 389.

https://doi.org/10.1182/blood.V110.11.389.389

Published: 2007

Journal Articles

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

Farhad Ravandi, MD, James Foran, MD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, William Wierda, MD, PhD, Patricia Boone, Gautam Borthakur, Trish Sweeney, PhD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 904.

https://doi.org/10.1182/blood.V110.11.904.904

Published: 2007

Journal Articles

A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB).

Angelina The, MD, Yufeng Li, PhD, Vishnu Reddy, MD, Randall Davis, MD, Melissa Baird, MD, James Foran, MD

Blood (2007) 110 (11): 4430.

https://doi.org/10.1182/blood.V110.11.4430.4430

Published: 2007

Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD

Blood (2006) 108 (11): 2711.

https://doi.org/10.1182/blood.V108.11.2711.2711

Published: 2006

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

Phase I Study of Clofarabine with Standard-Dose Infusional Cytarabine (Ara-C) as Intensive Induction Therapy for Newly-Diagnosed De Novo Acute Myeloid Leukemia in Older Adults Age ≥60 Years.

Phase II Study of R-CHOP Followed by 90 Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.

A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies.

A Comparative Study of Diffuse Large B-Cell Lymphoma (DLBCL) between African Americans and Caucasians: Single-Center Experience at the University of Alabama at Birmingham (UAB).

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only